Bellicum Pharmaceuticals to Present at the Barclay

HOUSTON, March 08, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM ), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Rick Fair, President and CEO, is scheduled to present a corporate overview at the Barclays Global Healthcare Conference on Wednesday, March 15 at 4:20 p.m. EDT in Miami, FL.

A live webcast of the presentation may be accessed from the  News & Events  section of the Bellicum website. An archived version of the webcast will be available for replay for at least two weeks following the event.

About Bellicum Pharmaceuticals Bellicum is a leader in developing novel, controllable cellular immunotherapies for cancers and for orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. More information can be found at  www.bellicum.com .

Investors: Bellicum Pharmaceuticals Alan Musso, CFO 832-384-1116 amusso@bellicum.com Media: BMC Communications Brad Miles, 646-513-3125 bmiles@bmccommunications.com